| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
P-THP is a new conceptional drug made by conjugation of pre-existing anticancer drug pirarubicin (THP) and polymer using nanomedicine technique. P-THP exhibits highly selective accumulation in solid tumors after intravenous injection by virtue of the enhanced permeability and retention (EPR) effect of high molecular drug in solid tumors. Moreover, P-THP releases active free THP more in the acidic environments in the tumor tissue than in the pH of normal tissue. Another advantage of P-THP is the cellular uptake rate: cancer cells incorporate free THP much more rapidly than other anthracyclines such as doxorubicin and epirubicin, through their highly upregulated cell membrane transporter system.
In this study, we obtained the possibility that the nanomedicine-derived P-THP can express its higher drug delivery into tumor and lower toxicity to the host even in the gynecologic malignancies.
|
